423 related articles for article (PubMed ID: 33657372)
1. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.
Branigan TB; Kozono D; Schade AE; Deraska P; Rivas HG; Sambel L; Reavis HD; Shapiro GI; D'Andrea AD; DeCaprio JA
Cell Rep; 2021 Mar; 34(9):108808. PubMed ID: 33657372
[TBL] [Abstract][Full Text] [Related]
2. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy.
Wolter P; Hanselmann S; Pattschull G; Schruf E; Gaubatz S
Oncotarget; 2017 Feb; 8(7):11160-11172. PubMed ID: 28061449
[TBL] [Abstract][Full Text] [Related]
3. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress.
Li F; Kozono D; Deraska P; Branigan T; Dunn C; Zheng XF; Parmar K; Nguyen H; DeCaprio J; Shapiro GI; Chowdhury D; D'Andrea AD
Mol Cell; 2020 Nov; 80(3):410-422.e6. PubMed ID: 33108758
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous expression of MMB-FOXM1 complex components enables efficient bypass of senescence.
Kumari R; Hummerich H; Shen X; Fischer M; Litovchick L; Mittnacht S; DeCaprio JA; Jat PS
Sci Rep; 2021 Nov; 11(1):21506. PubMed ID: 34728711
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed
Tan J; Ma J; Zhang W; Zhao J; Liu K
J Thorac Dis; 2023 Jun; 15(6):3350-3358. PubMed ID: 37426130
[TBL] [Abstract][Full Text] [Related]
6. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
Warren NJH; Eastman A
J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
[TBL] [Abstract][Full Text] [Related]
8. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
[TBL] [Abstract][Full Text] [Related]
9. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
10. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Nair J; Huang TT; Murai J; Haynes B; Steeg PS; Pommier Y; Lee JM
Oncogene; 2020 Aug; 39(33):5520-5535. PubMed ID: 32647134
[TBL] [Abstract][Full Text] [Related]
11. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.
Chung S; Vail P; Witkiewicz AK; Knudsen ES
Clin Cancer Res; 2019 Apr; 25(7):2290-2304. PubMed ID: 30538111
[TBL] [Abstract][Full Text] [Related]
12. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
13. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
Tao L; Cao Y; Wei Z; Jia Q; Yu S; Zhong J; Wang A; Woodgett JR; Lu Y
Toxicol Appl Pharmacol; 2017 Dec; 337():85-94. PubMed ID: 29074359
[TBL] [Abstract][Full Text] [Related]
14. DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells.
Li H; Sun L; Li H; Lv X; Semukunzi H; Li R; Yu J; Yuan S; Lin S
Cell Death Dis; 2017 May; 8(5):e2810. PubMed ID: 28542137
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
Mak JP; Man WY; Ma HT; Poon RY
Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
[TBL] [Abstract][Full Text] [Related]
17. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb.
Down CF; Millour J; Lam EW; Watson RJ
Biochim Biophys Acta; 2012 Aug; 1819(8):855-62. PubMed ID: 22513242
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
19. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
20. MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells.
Hsieh NT; Huang CY; Li CC; Wang IC; Lee MF
J Cell Physiol; 2019 Jul; 234(7):11265-11275. PubMed ID: 30499104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
